Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignant Thyroid Gland Neoplasm”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Early research (Phase 1)Active Not RecruitingNCT03420963
What this trial is testing

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Who this might be right for
Recurrent Cutaneous MelanomaRecurrent Lip and Oral Cavity CarcinomaRecurrent Malignant Endocrine Neoplasm+25 more
M.D. Anderson Cancer Center 12
Early research (Phase 1)Looking for participantsNCT04119024
What this trial is testing

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmMetastatic MelanomaPathologic Stage IIIC Cutaneous Melanoma AJCC v8+14 more
Anusha Kalbasi 18
Early research (Phase 1)Study completedNCT00667641
What this trial is testing

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Who this might be right for
Breast CancerColorectal CancerHead and Neck Cancer+6 more
University of Medicine and Dentistry of New Jersey 16
Early research (Phase 1)Study completedNCT01638533
What this trial is testing

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Who this might be right for
GliomaHematopoietic and Lymphoid Cell NeoplasmLymphoma+47 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439292
What this trial is testing

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Early research (Phase 1)Study completedNCT01709435
What this trial is testing

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent Primary Central Nervous System Neoplasm+4 more
National Cancer Institute (NCI) 41
Early research (Phase 1)Active Not RecruitingNCT01552434
What this trial is testing

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Who this might be right for
Advanced Malignant NeoplasmCastleman DiseaseDigestive System Carcinoma+36 more
M.D. Anderson Cancer Center 155
Not applicableStudy completedNCT04821336
What this trial is testing

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

Who this might be right for
Thyroid Cancer
Institut Claudius Regaud 30
Testing effectiveness (Phase 2)Study completedNCT02432274
What this trial is testing

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Who this might be right for
TumorsSolid Malignant TumorsOsteosarcoma+1 more
Eisai Limited 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592
What this trial is testing

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Who this might be right for
Adrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more
National Cancer Institute (NCI) 109
Testing effectiveness (Phase 2)Ended earlyNCT04985604
What this trial is testing

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorCRAF Gene Amplification+20 more
Day One Biopharmaceuticals, Inc. 23
Early research (Phase 1)Active Not RecruitingNCT03435952
What this trial is testing

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Who this might be right for
Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous System+9 more
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30